Who Paid My Doc
Richard Hammer
Hematology Columbia, MO Medical Doctor
NPI 1750342218 CMS profile 583730
1 Hospital Dr, Columbia, MO 65212
General payments
$103,396
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$57,183
Through program year 2025, Richard Hammer of Columbia, MO is reported in the CMS Open Payments database as having received $103,396 across 46 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $57,183 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 98th percentile of Hematology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $114 | 2 | |
| 2024 | General | $1,173 | 4 | |
| 2023 | General | $11,928 | 21 | |
| 2022 | General | $70,611 | 5 | |
| 2021 | General | $910 | 1 | |
| 2020 | General | $8,450 | 5 | |
| 2019 | General | $10,209 | 8 |
Beside peers
- Richard Hammer
- Hematology median
- Middle half of Hematology
- National median
In program year 2025, general payments to Richard Hammer were reported at $114. Among 90 Hematology profiles paid that year, the median was $118 and the middle half received between $38 and $729.
Show as a table
| Year | Richard Hammer | Hematology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $10,209 | $86 | $33–$300 | $163 |
| 2020 | $8,450 | $120 | $45–$4,916 | $114 |
| 2021 | $910 | $556 | $90–$2,631 | $132 |
| 2022 | $70,611 | $96 | $38–$1,275 | $149 |
| 2023 | $11,928 | $85 | $33–$360 | $160 |
| 2024 | $1,173 | $112 | $30–$991 | $164 |
| 2025 | $114 | $118 | $38–$729 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Billing to Medicare
Part B · data year 2024 · 27 billing codesPaid by Medicare
$31,493
Medicare patients
183
Services billed
1,269
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 50% | |
| Chronic kidney disease | 40% | |
| Heart failure | 38% | |
| Diabetes | 37% | |
| Depression | 37% | |
| COPD | 31% | |
| Atrial fibrillation | 30% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
46 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Hematology in Missouri
Related records
Hematology in Missouri
Practitioners in the same specialty and state, ranked by reported value.
All Hematology
Everyone recorded under this specialty, nationwide.
Doctors in Missouri
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.